PD-166326

PD-166326 is a potent small molecule inhibitor of protein tyrosine kinases in the pyridopyrimidine class. It acts as an ATP-competitive dual inhibitor of BCR-Abl and Src family kinases. The compound has demonstrated high potency against wild-type Bcr-Abl and certain mutant forms that confer resistance to imatinib (notably P-loop mutations), making it a candidate for overcoming resistance in chronic myeloid leukemia (CML). Preclinical studies have shown activity against various cancer cell lines and CML-like disease models in mice. Developed by Pfizer for oncology indications—primarily neoplasms—it has not advanced beyond preclinical or early clinical development[1][7][10].

Other names

185039-91-20H77F2T4U3Pyrido(2,3-d)pyrimidin-7(8H)-one 6-(2,6-dichlorophenyl)-2-((3-(hydroxymethyl)phenyl)amino)-8-methyl-6-(2,6-Dichlorophenyl)-2-[[3-(hydroxymethyl)phenyl]amino]-8-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one